Nemolizumab is a humanized monoclonal antibody that targets the interleukin-31 receptor A (IL-31RA), thereby blocking IL-31-mediated pruritus signaling pathways [1,2,3,4]. The gene discussed is IL31RA; the disease is Pruritus.